Nabriva Therapeutics plc
NBRVF · OTC
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $3,069 | $3,041 | $2,955 | $2,596 |
| - Cash | $2,182 | $1,798 | $12,414 | $14,647 |
| + Debt | $540 | $542 | $5,221 | $6,132 |
| Enterprise Value | $1,427 | $1,785 | -$4,239 | -$5,919 |
| Revenue | $2,574 | $7,590 | $10,439 | $8,784 |
| % Growth | -66.1% | -27.3% | 18.8% | – |
| Gross Profit | -$6,500 | $3,152 | -$5,910 | $4,368 |
| % Margin | -252.5% | 41.5% | -56.6% | 49.7% |
| EBITDA | -$12,006 | -$8,485 | -$22,305 | -$10,811 |
| % Margin | -466.4% | -111.8% | -213.7% | -123.1% |
| Net Income | -$12,062 | -$8,700 | -$22,778 | -$11,514 |
| % Margin | -468.6% | -114.6% | -218.2% | -131.1% |
| EPS Diluted | -3.73 | -2.72 | -7.32 | -4.21 |
| % Growth | -37.1% | 62.8% | -73.9% | – |
| Operating Cash Flow | $511 | -$5,618 | -$1,625 | -$6,177 |
| Capital Expenditures | $0 | -$3 | -$9 | -$103 |
| Free Cash Flow | $511 | -$5,621 | -$1,634 | -$6,280 |